secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001615219-23-000055
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve amended stock purchase plan adding 125,000 shares at 2023 annual meeting
--------------------------------------------------------------------------------

- All three Class II director nominees (David Arthur, Bruce McCreedy, Jonathan Lieber) elected with over 267,000 votes each.
- Amended ESPP approved: reserve increased by 125,000 shares, with annual automatic increase (2% or 75k shares) through 2028.
- Non-binding advisory vote on executive compensation approved with 216,044 for, 85,774 against.
- Ratification of Ernst & Young as auditor for FY2023 approved with 913,353 for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/0001615219-23-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521923000055/flks-20230614.htm
  HTML page:      https://secwatch.observer/filing/0001615219-23-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer